Early Breast Cancer Caregiver Survey

The pan-Canadian Oncology Drug Review (pCODR) makes recommendations about whether the provincial health plans should pay for new cancer drugs. pCODR will soon be reviewing the use of Herceptin-Perjeta combination therapy to treat HER2-positive early breast cancer.

Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process. We would also like to speak with family friends about their experience caring for women being treated with Herceptin-Perjeta combination therapy.

We would like to thank everyone who agrees to share their experiences.

* 1. What is your relationship to the breast cancer patient ?

* 2. How would you describe the severity of the challenges you have faced as a caregiver on a scale of 1 (not all severe) to 5 (very severe)? Please elaborate in the comments section.

  1 2 3 4 5
Financial
Health
Educational
Social
Professional

* 3. Have you faced any financial challenges as a caregiver?

* 4. Have you or the patient needed financial assistance due to the costs of breast cancer or its treatment?

* 5. Has the patient for whom you are caring been treated with Herceptin-Perjeta combination therapy?

* 6. If yes, how long were they treated with Herceptin-Perjeta?

* 7. Has their breast cancer recurred since they began treatment?

* 8. Given your current knowledge about cancer - how you feel about the possibility of the cancer’s recurrence?

* 9. From your perspective, were the side effects from Herceptin-Perjeta better or worse than those associated with other therapies that the patient has received?

* 10. Did the patient have any difficulty accessing Herceptin-Perjeta?

* 11. What country are you from?

* 12. If you are Canadian, what province are you from?

T